BRCA2 germline mutations in male breast cancer cases and breast cancer families.

PubWeight™: 2.75‹?› | Rank: Top 1%

🔗 View Article (PMID 8673091)

Published in Nat Genet on May 01, 1996

Authors

F J Couch1, L M Farid, M L DeShano, S V Tavtigian, K Calzone, L Campeau, Y Peng, B Bogden, Q Chen, S Neuhausen, D Shattuck-Eidens, A K Godwin, M Daly, D M Radford, S Sedlacek, J Rommens, J Simard, J Garber, S Merajver, B L Weber

Author Affiliations

1: Department of Medicine, 1010 Stellar Chance Laboratories, University of Pennsylvania, Philadelphia, 19104, USA.

Articles citing this

Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. Am J Hum Genet (2001) 3.75

Population genetics of BRCA1 and BRCA2. Am J Hum Genet (1997) 3.28

Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer. Am J Hum Genet (2000) 2.77

Multidisciplinary meeting on male breast cancer: summary and research recommendations. J Clin Oncol (2010) 2.53

Mutation analysis of BRCA1 and BRCA2 in a male breast cancer population. Am J Hum Genet (1997) 2.53

Moderate frequency of BRCA1 and BRCA2 germ-line mutations in Scandinavian familial breast cancer. Am J Hum Genet (1997) 2.33

Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families. Am J Hum Genet (1997) 2.31

Mutations in BRCA1 and BRCA2 in breast cancer families: are there more breast cancer-susceptibility genes? Am J Hum Genet (1997) 2.15

Interaction between the product of the breast cancer susceptibility gene BRCA2 and DSS1, a protein functionally conserved from yeast to mammals. Mol Cell Biol (1999) 1.77

BRCA1 and BRCA2 mutations in a population-based study of male breast cancer. Breast Cancer Res (2001) 1.66

Breast cancer risk among male BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst (2007) 1.66

BRCA2 in American families with four or more cases of breast or ovarian cancer: recurrent and novel mutations, variable expression, penetrance, and the possibility of families whose cancer is not attributable to BRCA1 or BRCA2. Am J Hum Genet (1997) 1.60

Truncated BRCA2 is cytoplasmic: implications for cancer-linked mutations. Proc Natl Acad Sci U S A (1999) 1.54

A low proportion of BRCA2 mutations in Finnish breast cancer families. Am J Hum Genet (1997) 1.46

Analysis of the RNASEL gene in familial and sporadic prostate cancer. Am J Hum Genet (2002) 1.41

Genetic heterogeneity in hereditary breast cancer: role of BRCA1 and BRCA2. Am J Hum Genet (1996) 1.24

Analysis of BRCA1 and BRCA2 mutations in Hungarian families with breast or breast-ovarian cancer. Am J Hum Genet (1997) 1.16

Genetic and functional analysis of CHEK2 (CHK2) variants in multiethnic cohorts. Int J Cancer (2007) 1.09

A novel BRCA2 mutation in an Indonesian family found with a new, rapid, and sensitive mutation detection method based on pooled denaturing gradient gel electrophoresis and targeted sequencing. J Clin Pathol (2005) 1.08

Germline BRCA2 mutations in men with breast cancer. Br J Cancer (1997) 1.07

Mutations in BRCA2 and PALB2 in male breast cancer cases from the United States. Breast Cancer Res Treat (2010) 1.06

PALB2 and breast cancer: ready for clinical translation! Appl Clin Genet (2013) 1.03

Founder BRCA1/2 mutations among male patients with breast cancer in Israel. Am J Hum Genet (1999) 1.03

Hereditary breast cancer in Jews. Fam Cancer (2004) 0.99

Prevalence of BRCA1 and BRCA2 mutations in non-familial breast cancer patients with high risks in Korea: the Korean Hereditary Breast Cancer (KOHBRA) Study. Breast Cancer Res Treat (2012) 0.95

RAD51 and breast cancer susceptibility: no evidence for rare variant association in the Breast Cancer Family Registry study. PLoS One (2012) 0.93

BRCA1 and BRCA2 mutation status and cancer family history of Danish women affected with multifocal or bilateral breast cancer at a young age. J Med Genet (2001) 0.92

Clinicopathological study of male breast carcinoma: 24 years of experience. Ann Saudi Med (2009) 0.92

BRCA2 mutations in hereditary breast and ovarian cancer in France. Am J Hum Genet (1997) 0.91

BRCA1/2 mutation analysis in male breast cancer families from North West England. Fam Cancer (2007) 0.90

Using gene carrier probability to select high risk families for identifying germline mutations in breast cancer susceptibility genes. J Med Genet (1998) 0.90

BRCA1 and BRCA2 mutations in central and southern Italian patients. Breast Cancer Res (2000) 0.88

BRCA2 mutations in 154 finnish male breast cancer patients. Neoplasia (2004) 0.88

Ashkenazi Jews and breast cancer: the consequences of linking ethnic identity to genetic disease. Am J Public Health (2006) 0.87

Inherited BRCA2 mutations in African Americans with breast and/or ovarian cancer: a study of familial and early onset cases. Hum Genet (2003) 0.85

Polymorphisms in PTEN in breast cancer families. J Med Genet (1999) 0.83

Subjective versus objective risk in genetic counseling for hereditary breast and/or ovarian cancers. J Exp Clin Cancer Res (2009) 0.83

Family history of cancer and germline BRCA2 mutations in sporadic exocrine pancreatic cancer. Gut (2002) 0.83

Novel nonsense mutation of BRCA2 gene in a Moroccan man with familial breast cancer. Afr Health Sci (2014) 0.82

High detection rate for BRCA2 mutations in male breast cancer families from North West England. Fam Cancer (2001) 0.82

Evidence for an ancient BRCA1 mutation in breast cancer patients of Yoruban ancestry. Fam Cancer (2008) 0.81

The occurrence of germline BRCA1 and BRCA2 sequence alterations in Slovenian population. BMC Med Genet (2011) 0.80

Diverse effect of WWOX overexpression in HT29 and SW480 colon cancer cell lines. Tumour Biol (2014) 0.80

Prognostic value of loss of heterozygosity at BRCA2 in human breast carcinoma. Br J Cancer (1997) 0.80

Similar prevalence of founder BRCA1 and BRCA2 mutations among Ashkenazi and non-Ashkenazi men with breast cancer: evidence from 261 cases in Israel, 1976-1999. Eur J Med Genet (2007) 0.79

Germline Mutation of the CCK Receptor: A Novel Biomarker for Pancreas Cancer. Clin Transl Gastroenterol (2016) 0.78

Identification of a new BRCA2 large genomic deletion associated with high risk male breast cancer. Hered Cancer Clin Pract (2015) 0.76

ABRAXAS (FAM175A) and Breast Cancer Susceptibility: No Evidence of Association in the Breast Cancer Family Registry. PLoS One (2016) 0.76

Male breast cancer in a multi-gene panel testing cohort: insights and unexpected results. Breast Cancer Res Treat (2016) 0.75

Brca2 deficiency leads to T cell loss and immune dysfunction. Mol Cells (2015) 0.75

In vitro phosphorylation of BRCA2 by the checkpoint kinase CHEK2. Br J Cancer (2008) 0.75

Invasive ductal breast carcinoma underneath a lipoma in a male patient. J Clin Aesthet Dermatol (2012) 0.75

Mutational spectrum in breast cancer associated BRCA1 and BRCA2 genes in Colombia. Colomb Med (Cali) (2017) 0.75

Influence of the Angelina Jolie Announcement and Insurance Reimbursement on Practice Patterns for Hereditary Breast Cancer. J Breast Cancer (2017) 0.75

Treatment of Male Breast Cancer by Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade and Response Prediction Using Novel Optical Tomography Imaging: A Case Report. Cureus (2017) 0.75

Strictly defined familial male breast cancer. Fam Cancer (2011) 0.75

BRCA1 and BRCA2 mutations in males with familial breast and ovarian cancer syndrome. Results of a Spanish multicenter study. Fam Cancer (2015) 0.75

Descriptive characteristics of prostate cancer in patients with a history of primary male breast cancer - a SEER analysis. BMC Cancer (2017) 0.75

Articles by these authors

A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science (1994) 36.53

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst (1998) 22.10

Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet (1997) 15.38

The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet (2000) 15.19

Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet (1998) 15.09

The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell (1993) 13.54

A cell cycle regulator potentially involved in genesis of many tumor types. Science (1994) 13.00

Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J Clin Invest (1999) 8.38

Beta-defensins: linking innate and adaptive immunity through dendritic and T cell CCR6. Science (1999) 7.86

Multisite phosphorylation of a CDK inhibitor sets a threshold for the onset of DNA replication. Nature (2001) 7.31

Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. N Engl J Med (1996) 7.09

BRCA1 mutations in primary breast and ovarian carcinomas. Science (1994) 6.81

The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat Genet (1996) 6.43

Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst (1998) 6.06

Duplication of CaMV 35S Promoter Sequences Creates a Strong Enhancer for Plant Genes. Science (1987) 6.00

Letter: Grading of angina pectoris. Circulation (1976) 5.86

Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science (2000) 5.62

AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. Proc Natl Acad Sci U S A (1992) 5.24

Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int J Cancer (1995) 5.24

The diastrophic dysplasia gene encodes a novel sulfate transporter: positional cloning by fine-structure linkage disequilibrium mapping. Cell (1994) 5.21

A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol (2007) 5.12

A candidate prostate cancer susceptibility gene at chromosome 17p. Nat Genet (2001) 5.06

Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium. JAMA (1997) 4.79

Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor beta(1). J Exp Med (2001) 4.71

The relation between genotype and phenotype in cystic fibrosis--analysis of the most common mutation (delta F508). N Engl J Med (1990) 4.70

LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells. J Exp Med (2000) 4.68

A collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene. Implications for presymptomatic testing and screening. JAMA (1995) 4.45

A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes. Nat Genet (1996) 4.38

BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med (1997) 4.33

Genomic DNA sequence of the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Genomics (1991) 4.27

Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size. Nat Nanotechnol (2011) 4.22

Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice. Nat Med (1997) 4.10

Development of donor-derived prostate cancer in a recipient following orthotopic heart transplantation. JAMA (1997) 3.94

Stable interaction between the products of the BRCA1 and BRCA2 tumor suppressor genes in mitotic and meiotic cells. Mol Cell (1998) 3.86

An evaluation of genetic heterogeneity in 145 breast-ovarian cancer families. Breast Cancer Linkage Consortium. Am J Hum Genet (1995) 3.81

A Grb2-associated docking protein in EGF- and insulin-receptor signalling. Nature (1996) 3.79

Identification of bile duct stones in patients undergoing laparoscopic cholecystectomy. Br J Surg (1991) 3.65

Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. N Engl J Med (1998) 3.60

Life expectancy, economic inequality, homicide, and reproductive timing in Chicago neighbourhoods. BMJ (1997) 3.56

Human mitogen-activated protein kinase kinase 4 as a candidate tumor suppressor. Cancer Res (1997) 3.55

Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol (1998) 3.40

Common origins of BRCA1 mutations in Canadian breast and ovarian cancer families. Nat Genet (1994) 3.38

The quaking gene product necessary in embryogenesis and myelination combines features of RNA binding and signal transduction proteins. Nat Genet (1996) 3.35

RAD51 interacts with the evolutionarily conserved BRC motifs in the human breast cancer susceptibility gene brca2. J Biol Chem (1997) 3.26

Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst (1999) 3.26

Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families. Nat Med (1996) 3.07

Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat Genet (1994) 3.05

Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res (1995) 3.04

BRG1, a component of the SWI-SNF complex, is mutated in multiple human tumor cell lines. Cancer Res (2000) 3.01

Breast cancer genetics: what we know and what we need. Nat Med (2001) 2.96

Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer. Nat Genet (1996) 2.93

Arrest of the cell cycle by the tumour-suppressor BRCA1 requires the CDK-inhibitor p21WAF1/CiP1. Nature (1997) 2.93

The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%. Nat Genet (1996) 2.82

BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing. JAMA (1997) 2.78

Mutation detection using a novel plant endonuclease. Nucleic Acids Res (1998) 2.78

CCAAT enhancer- binding protein beta is required for normal hepatocyte proliferation in mice after partial hepatectomy. J Clin Invest (1998) 2.74

Gallbladder muscle dysfunction in patients with chronic acalculous disease. Gastroenterology (2001) 2.73

AIDS and self-organization among intravenous drug users. Int J Addict (1987) 2.73

Recommendations for follow-up care of individuals with an inherited predisposition to cancer. I. Hereditary nonpolyposis colon cancer. Cancer Genetics Studies Consortium. JAMA (1997) 2.73

Rapid nonradioactive detection of the major cystic fibrosis mutation. Am J Hum Genet (1990) 2.72

The relation of risk factors to the development of atherosclerosis in saphenous-vein bypass grafts and the progression of disease in the native circulation. A study 10 years after aortocoronary bypass surgery. N Engl J Med (1984) 2.70

Mutations in the BRCA1 gene in families with early-onset breast and ovarian cancer. Nat Genet (1994) 2.66

Germline mutations of the p53 tumor-suppressor gene in children and young adults with second malignant neoplasms. N Engl J Med (1992) 2.64

Do rehabilitative nursing homes improve the outcomes of care? J Am Geriatr Soc (1996) 2.63

Mutations in the homeodomain of the human SIX3 gene cause holoprosencephaly. Nat Genet (1999) 2.57

Characterization of the distinct orthotopic bone-forming activity of 14 BMPs using recombinant adenovirus-mediated gene delivery. Gene Ther (2004) 2.55

Mutations and polymorphisms in the familial early-onset breast cancer (BRCA1) gene. Breast Cancer Information Core. Hum Mutat (1996) 2.54

Attitudes about genetic testing for breast-ovarian cancer susceptibility. J Clin Oncol (1994) 2.52

Genetic counseling for families with inherited susceptibility to breast and ovarian cancer. JAMA (1993) 2.51

Assessment and counseling for women with a family history of breast cancer. A guide for clinicians. JAMA (1995) 2.50

DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis. Hum Mol Genet (2001) 2.50

Role of nonimmune IgG bound to PfEMP1 in placental malaria. Science (2001) 2.50

Somatization symptoms in pediatric abdominal pain patients: relation to chronicity of abdominal pain and parent somatization. J Abnorm Child Psychol (1991) 2.50

Mapping of a gene for type 2 diabetes associated with an insulin secretion defect by a genome scan in Finnish families. Nat Genet (1996) 2.48

Genetic determination of exocrine pancreatic function in cystic fibrosis. Am J Hum Genet (1992) 2.48

Recent advances in breast cancer biology. Curr Opin Oncol (1999) 2.46

Effects of individualized breast cancer risk counseling: a randomized trial. J Natl Cancer Inst (1995) 2.45

Germline BRCA1 185delAG mutations in Jewish women with breast cancer. Lancet (1996) 2.40

Analysis of missense variation in human BRCA1 in the context of interspecific sequence variation. J Med Genet (2004) 2.40

BRCA1 physically associates with p53 and stimulates its transcriptional activity. Oncogene (1998) 2.39